Indeed, we showed that miR-192-5p specifically targets BCL2 promoter, and the low BCL2 gene expression in our MDS responder patients hints at a suppressive role of miR-192-5p, possibly correlating with inhibition of proliferation in this patients’ subgroup. The gene discussed is BCL2; the disease is myelodysplastic syndrome.